TY - JOUR
T1 - What Is Hidden Behind Yellow Pixels
T2 - from Pathology to Intravascular Imaging of Atherosclerotic Plaque
AU - Trusinskis, Karlis
AU - Knoka, Evija
AU - Caunite, Laima
AU - Karantajere, Mairita
AU - Lapsovs, Maris
AU - Paeglite, Sandra
AU - Briede, Ieva
AU - Grikis, Karlis
AU - Jegere, Sanda
AU - Kumsars, Indulis
AU - Narbute, Inga
AU - Roze, Rudolfs
AU - Sondore, Dace
AU - Erglis, Andrejs
N1 - Funding Information:
Karlis Trusinskis reports research grants from Sanofi and Novartis companies for Early Atherosclerosis registry. He also reports lecture honoraria from Servier, Boehringer Ingelheim, Berlin-Chemie, AstraZeneca, Novartis, Sanofi and Bayer. And he has received support for attending meetings for the Latvian Society of Hypertension and Atherosclerosis, Berlin-Chemie, Servier and Boehringer Ingelheim. He also reports participation on a Data Safety Monitoring Board or Advisory Board for Novo Nordisk and Sanofi.
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2022/2
Y1 - 2022/2
N2 - Purpose of Review: Intravascular imaging systems can identify lipid-rich and vulnerable plaques and help in treatment guidance. The comparability of different intracoronary imaging methods remains unclear. In this paper, we review atherosclerotic plaque pathology, plaque-stabilising effects of different lipid-lowering therapies and usage of intravascular imaging modalities. We present the results of our study in which we evaluated the correlation of the intravascular ultrasound iMAP system (iMAP-IVUS) and near-infrared spectroscopy (NIRS) in the diagnosis of vulnerable coronary plaques. Recent Findings: Lipids have an essential contribution to plaque evolution and vulnerability. Increase in plaque vulnerability alone even without increase in plaque burden defines progression of atherosclerosis. Lipidic tissue has a significant diagnostic value in patient risk stratification and can serve as a treatment target. Different vulnerable plaque parameters can be visualised with iMAP-IVUS and NIRS. Summary: Intravascular imaging systems can differ with regard to their sensitivity, specificity and limitations. Lipid-lowering therapy is crucial in plaque stabilisation.
AB - Purpose of Review: Intravascular imaging systems can identify lipid-rich and vulnerable plaques and help in treatment guidance. The comparability of different intracoronary imaging methods remains unclear. In this paper, we review atherosclerotic plaque pathology, plaque-stabilising effects of different lipid-lowering therapies and usage of intravascular imaging modalities. We present the results of our study in which we evaluated the correlation of the intravascular ultrasound iMAP system (iMAP-IVUS) and near-infrared spectroscopy (NIRS) in the diagnosis of vulnerable coronary plaques. Recent Findings: Lipids have an essential contribution to plaque evolution and vulnerability. Increase in plaque vulnerability alone even without increase in plaque burden defines progression of atherosclerosis. Lipidic tissue has a significant diagnostic value in patient risk stratification and can serve as a treatment target. Different vulnerable plaque parameters can be visualised with iMAP-IVUS and NIRS. Summary: Intravascular imaging systems can differ with regard to their sensitivity, specificity and limitations. Lipid-lowering therapy is crucial in plaque stabilisation.
KW - Atherosclerotic plaque
KW - Coronary artery disease
KW - iMAP-IVUS
KW - Intravascular imaging
KW - NIRS
UR - https://www.scopus.com/pages/publications/85124141403
U2 - 10.1007/s11883-022-00990-3
DO - 10.1007/s11883-022-00990-3
M3 - Review article
C2 - 35107762
AN - SCOPUS:85124141403
SN - 1523-3804
VL - 24
SP - 97
EP - 108
JO - Current Atherosclerosis Reports
JF - Current Atherosclerosis Reports
IS - 2
ER -